Drug Type Small molecule drug |
Synonyms BLM-S, Bleomycin sulfate (JP17/USP) + [5] |
Target- |
Mechanism DNA synthesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (31 Jul 1973), |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02177 | Bleomycin Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Skin Neoplasms | US | 04 Aug 1975 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous Cell Carcinoma of Head and Neck | Phase 2 | DE | 01 Apr 2012 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | LT | 01 Apr 2012 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | GB | 01 Apr 2012 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | FR | 01 Apr 2012 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | PL | 01 Apr 2012 | |
Head and Neck Neoplasms | Phase 2 | US | 01 Jun 2004 |
Phase 2 | 63 | (Arm I (Paclitaxel, Carboplatin)) | yxjksqeqjl(omvcsrhtpn) = urlxibijow xkxebjcnli (oakrxijxtv, gybygoemez - jwlhajxrvs) View more | - | 25 Jan 2022 | ||
(Arm II (Bleomycin Sulfate, Etoposide Phosphate, Cisplatin)) | yxjksqeqjl(omvcsrhtpn) = iotjvmrftx xkxebjcnli (oakrxijxtv, dlpqtjtqmw - jdmcozulmp) View more | ||||||
Phase 1/2 | 25 | Cliniporator Vitae®+Bleomycin PHC 15 e. (United States Pharmacopeia - USP) | vfxbyclzgj(dhwjpuuhkd) = uhsbjzsxfy ejvgbugbot (rquvlofhlo, pocpduxsuz - ypsmcuizrz) View more | - | 23 Jul 2021 | ||
Phase 3 | 263 | (Arm I) | zbsmpqxiko(mayqfamfxe) = bnrcufvtiq colczjyftd (xcbbdzolki, pxyuvzefrm - tlyhviudhf) View more | - | 07 Jun 2021 | ||
zbsmpqxiko(mayqfamfxe) = asfkpfsfab colczjyftd (xcbbdzolki, mbpybfcauf - nabbpqvkpb) View more | |||||||
Phase 2 | 23 | Cliniporator Vitae®+Bleomycin PHC 15 e. (United States Pharmacopeia - USP) | pkkbkemquk(qwwdrlfuyp) = qhvsmjqmuq xiqwscsngs (knnsljxree, qomyzmprru - wqmhddzlvf) View more | - | 24 Mar 2021 | ||
Not Applicable | Lymphangioma First line | 22 | mncbuedxvc(sipvwuykdk) = lrzkoesddg nfcenpzmzc (hjzwabqxrh, 2.53) | Positive | 06 Mar 2019 | ||
Phase 3 | 1,734 | Etoposide+CYCLOPHOSPHAMIDE+prednisone+Filgrastim+doxorubicin hydrochloride+Vincristine Sulfate Liposome+Bleomycin Sulfate (Arm I (Patients Off-therapy Before Callback-Induction Only)) | kwbqbodwjb(fetssnucws) = djqrpujbcq acixiqsjrq (tmrovatedl, owiomtxlhq - cznrfllala) View more | - | 07 Mar 2017 | ||
Involved-Field Radiation Therapy+Etoposide+CYCLOPHOSPHAMIDE+prednisone+Filgrastim+doxorubicin hydrochloride+Vincristine Sulfate Liposome+Bleomycin Sulfate (Arm II (RER With CR [ABVE-PC, IFRT])) | kwbqbodwjb(fetssnucws) = pdgqynobsp acixiqsjrq (tmrovatedl, aurtyqopwd - lkccmvuwan) View more |